Journal article

Trends in management of hip and knee osteoarthritis in general practice in Australia over an 11-year window: a nationwide cross-sectional survey

Kim L Bennell, Clare Bayram, Christopher Harrison, Caroline Brand, Rachelle Buchbinder, Romi Haas, Rana S Hinman

LANCET REGIONAL HEALTH-WESTERN PACIFIC | ELSEVIER | Published : 2021

Abstract

Background: We aimed to describe trends in knee and hip OA management by general medical practitioners (GPs) in Australia. Methods: We analysed cross-sectional survey data from the Bettering the Evaluation and Care of Health (BEACH) program (1,000 randomly-selected GPs annually recording 100 consecutive patient encounters) over two periods: Period one April 1, 2005-March 31, 2010 and period two April 1, 2010-March 31, 2016. This included data from 10,738 GPs and 1,073,800 patient encounters with 6,565 GPs and 9,196 patient encounters for hip/knee OA. Data were summarized using descriptive statistics and 95% confidence intervals around point estimates. Findings: Rate of knee OA problems manag..

View full abstract

Grants

Awarded by National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Translational Research in Musculoskeletal Pain


Awarded by NHMRC Investigator Fellowship


Awarded by NHMRC Senior Principal Research Fellowship


Awarded by NHMRC Early Career Fellowship


Awarded by NHMRC Senior Research Fellowship


Funding Acknowledgements

The authors thank the GP participants in the BEACH program and all members of the BEACH research team as well Professor Helena Britt for reviewing this manuscript prior to submission. During the period reported here, the BEACH project was funded by: AstraZeneca Pty Ltd (Australia) ; Australian Government Department of Health; Novartis Pharmaceuticals Australia Pty Ltd; Seqirus (Australia) Pty Ltd; Sanofi-Aventis Australia Pty Ltd; Australian Government Department of Veterans' Affairs; AbbVie Pty Ltd; Merck, Sharpe and Dohme (Australia) Pty Ltd; Pfizer Australia; National Prescribing Service; GlaxoSmithKline Australia Pty Ltd; Bayer Australia Ltd; Janssen-Cilag Pty Ltd; Abbott Australasia Pty Ltd; Wyeth Australia Pty Ltd; Roche Products Pty Ltd; Aventis Pharma Pty Ltd. Funding was provided for this report by the National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Translational Research in Musculoskeletal Pain (#1079078) . KLB is supported by an NHMRC Investigator Fellowship (#1174431) , RB by a NHMRC Senior Principal Research Fellowship (#1082138) , CH by a NHMRC Early Career Fellowship (#1163058) and RSH by a NHMRC Senior Research Fellowship (#1154217) . The funders of the BEACH study had no role in the preparation of this manuscript. The authors had full access to all of the data (including statistical reports and tables) in the study.